California voters face Proposition 38 on the November 2026 ballot, authorizing $8.4 billion in general obligation bonds to establish immunology and immunotherapy research funding split between a University of California-affiliated institute and grants to public or nonprofit institutions. Half the proceeds would target cancer, heart disease, and Alzheimer’s research, with requirements that resulting technologies and drugs be sold in the state at 20% below the national average price. Trader balance at even odds reflects competing pressures: support from philanthropists, the Alzheimer’s Association, and disease advocacy groups emphasizing potential cures and economic activity, versus concerns over roughly $500 million in annual General Fund debt service for 25 years amid broader state fiscal priorities and questions about research commercialization. Recent qualification for the ballot and early endorsements have shaped initial positioning, while upcoming polling, additional endorsements or opposition campaigns, and any shifts in federal research budgets could alter consensus before election day.